Status: Recruiting
Adaptive Radiation for Abdominopelvic Metastases
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Fox Chase Cancer CenterUpdated: Oct 29, 2025Locations: 1
Eligibility criteria
Subjects must have histologically or cytologically confirmed cancer that is meta... [+11]
Subjects must not be experiencing toxicity due to prior therapy that has not res... [+8]